Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/1617
Title: | Individual fracture risk and the cost-effectiveness of bisphosphonates in patients using oral glucocorticoids | Authors: | van Staa, T. GEUSENS, Piet Zhang, B. Leufkens, H. Boonen, A. Cooper, C. |
Issue Date: | 2007 | Publisher: | Oxford | Source: | RHEUMATOLOGY, 46(3). p. 460-466 | Abstract: | Objectives. There are few data on the cost-effectiveness of bisphosphonates with oral glucocorticoids (GCs). An individual patient-based pharmaco-economic model was developed. Methods. Data were obtained from a cohort of oral GC users aged 40+ (n = 190 000) in the UK General Practice Research Database. Individualized fracture and mortality risks were calculated specific for age, sex, daily and cumulative GC dose, indication and other clinical risk factors. UK costs of medication and direct costs of fracture were obtained from National Institute for Clinical Excellence and used to estimate costs per quality-adjusted life-year (QALY) gained and fracture prevented for bisphosphonates in patients treated for 5 yrs with GCs. Results. With the use of 5 mg GCs daily, the cost per one QALY gained with bisphosphonates was 41k UK pounds (95% confidence intervals 22–72k) in women aged <60 [men £40k (29–54k)], £17k (13–24k) in women aged 60–79 [men £43k (31–60k)], £5k (3–6k) in women aged 80+ [men £35k (25–46k)]. With 15 mg GC, these figures were £17k (14–21k), £13k (10–16k) and £15k (9–26k) in women and £22k (17–26k), £34 (23–53k) and £33k (27–42k) in men, respectively. When stratifying by overall fracture risk and life expectancy at the start of GC therapy, cost per QALY increased with decreasing life expectancy. Patients with rheumatoid arthritis had comparatively better cost-effectiveness, given higher fracture risk and better life expectancy. Conclusions. The cost-effectiveness of bisphosphonates varied substantially. Bisphosphonates can be considered cost-effective in patients with higher fracture risks, such as elderly patients (with a life expectancy over 5 yrs), and younger patients with a fracture history, low body mass index, rheumatoid arthritis or using high GC doses. | Keywords: | Glucocorticoids, Corticosteroids, Osteoporosis, Fracture, Iatrogenic disease, Cost-effectiveness | Document URI: | http://hdl.handle.net/1942/1617 | ISSN: | 1462-0324 | e-ISSN: | 1462-0332 | DOI: | 10.1093/rheumatology/kel249 | ISI #: | 000244427500018 | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2008 |
Appears in Collections: | Research publications |
Show full item record
SCOPUSTM
Citations
26
checked on Sep 2, 2020
WEB OF SCIENCETM
Citations
24
checked on Oct 4, 2024
Page view(s)
74
checked on Jul 28, 2023
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.